Herein, we explored our hypothesis that the combination approach using selective and brain-penetrant inhibitors, adagrasib and abemaciclib, would be effective for BM models of NSCLC with the genomic alterations of KRAS-G12C and CDKN2A loss. This evidence concerns the gene KRAS and non-small cell lung carcinoma.